Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi-7: Ivonescimab versus pembrolizumab as first-line treatment for PD-L1-high metastatic non-small cell lung cancer
CTR20251989Phase 3Active
- Sponsor
- CTTQ-Akeso
- Start
- Jul 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by CTTQ-Akeso. Started Jul 2025; status: active.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20251989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251989.